EP1221045A2 - Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles - Google Patents

Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles

Info

Publication number
EP1221045A2
EP1221045A2 EP00972748A EP00972748A EP1221045A2 EP 1221045 A2 EP1221045 A2 EP 1221045A2 EP 00972748 A EP00972748 A EP 00972748A EP 00972748 A EP00972748 A EP 00972748A EP 1221045 A2 EP1221045 A2 EP 1221045A2
Authority
EP
European Patent Office
Prior art keywords
receptor
antigen
antibody
test
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00972748A
Other languages
German (de)
English (en)
Inventor
Christian Reiter
Gerhard Cullmann
Meret Lakner
Andreas TRÜE
Sonja Dehnert
George Schwartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxoid Ely Ltd
Original Assignee
Connex Gesellschaft zur Optimierung von Forschung und Entwicklung mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connex Gesellschaft zur Optimierung von Forschung und Entwicklung mbH filed Critical Connex Gesellschaft zur Optimierung von Forschung und Entwicklung mbH
Priority to EP00972748A priority Critical patent/EP1221045A2/fr
Priority to DE20023799U priority patent/DE20023799U1/de
Priority claimed from PCT/EP2000/010057 external-priority patent/WO2001027612A2/fr
Publication of EP1221045A2 publication Critical patent/EP1221045A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Definitions

  • the invention relates to an immunochromatographic rapid test, in particular a test strip, for detecting an infection of a mammal with an acid-resistant microorganism.
  • A (a) a stool sample from the mammal is incubated using (aa) a receptor under conditions which allow complex formation of an analyte or an antigen from the acid-resistant microorganism with the receptor; or (ab) incubated at least two different receptors under conditions which allow complex formation of an analyte or antigen from the acid-resistant microorganism with the at least two receptors and wherein the receptor according to (aa) or the receptors according to (ab) an analyte or specifically binds / bind an antigen which, at least in part of the mammals after the intestinal passage, has a structure which corresponds to the native structure or the structure against which a mammal, after infection or immunization with the acid-resistant microorganism or an extract or lysate antibody or a protein thereof or a fragment thereof or
  • the acid-resistant microorganism is preferably a bacterium, in particular Helicobacter pylori, Helicobacter hepaticus, Campylobacter jejuni or Mycobacterium tuberculosis. It is further preferred that the receptor (s) bind to an epitope / epitopes of a catalase, urease or metalloproteinase.
  • the invention further relates to diagnostic compositions and test devices which contain the aforementioned components and packaging containing them. The detection of infection of a mammalian organism with a microbial pathogen or parasite can now be carried out in various, invasive, semi-invasive or non-invasive ways. All invasive methods require endoscopy and biopsy.
  • Body fluids and excretions such as serum, breathing air, urine, saliva, sweat or stool are preferably sampled and analyzed.
  • Diagnostic techniques can be divided into direct and indirect methods based on the proven parameters.
  • direct methods the presence of the pathogen or parasite, its constituents or their degradation products is verified by electron microscopy, optical characterization, mass spectrometry, measurement of the radioactive decay products or specific enzymatic reactions.
  • these procedures are often associated with a high level of equipment complexity (eg breath test).
  • Indirect methods on the other hand, rely on the detection of reactions of the host organism to the pathogen or the parasite, for example the presence of antibodies against antigens of the pathogen in the serum or in the saliva of the host.
  • pathogens described above have in common that they are viable and able to reproduce in the intestine of their host, in all cases in humans. So you have mechanisms that allow you to survive and multiply in the presence of the digestive and digestive systems active in the intestine. It is therefore likely that a large number of intact or almost intact pathogens or parasites will go away when excreted with the stool. With detection reagents, for example antibodies, which recognize the intact pathogens or parasites, these can usually be easily detected in the stool or in prepared stool samples.
  • pathogens and parasites that can occur in the stool on the one hand due to the relationships of the affected tissue (e.g. lungs, stomach, pancreas, duodenum, liver) to the gastrointestinal tract, but on the other hand they do not live in the intestine itself - and / or are capable of reproduction.
  • pathogens and parasites include, for example, Helicobacter pylori (H. pylori) and Helicobacter hepatis, Mycobacterium tuberculosis and other mycobacteria, Chlamydia pneumoniae, Legionella pneumophilae, Pneumocystis carinii, and others.
  • pathogens such as Legionella pneumophilae can be specifically detected using antigens that enter the urine through the kidneys. However, this only works if the amount in the urine is sufficient for the detection. Proof in the chair would be a welcome alternative.
  • the intestinal passage is associated with a strong attack by the digestive and degradation mechanisms of the intestinal flora. Molecular structures specific to the pathogen under consideration can be destroyed or their concentration greatly reduced.
  • the degradation of the pathogens in the intestine has also proven to be a problem for reliable detection in stool samples in other acid-resistant bacteria.
  • the number of germs in the stomach of an infected person is low compared to other bacteria that colonize the intestine.
  • germs and germ fragments have to travel a long way through the intestine, which is rich in proteases. The result of this is that only small amounts of intact proteins can be found in the stool, although it cannot be assumed that the same fragments of certain proteins always pass through the intestinal tract without damage.
  • EP 291 194 describes an analytical test device which contains a porous support with a specific binding reagent for an analyte which is mobile in the moist state and a permanently immobilized, unlabeled, specific binding reagent for the same analyte.
  • the object of the present invention is therefore to provide a corresponding simple and inexpensive test.
  • the invention relates to a method for detecting an infection of a mammal with an acid-resistant microorganism, wherein (a) a stool sample of the Incubated mammal using (aa) a receptor under conditions that allow complexation of an antigen from the acid-resistant microorganism with the receptor; or (ab) incubated at least two different receptors under conditions which allow complex formation of an antigen from the acid-resistant microorganism with the at least two receptors and wherein the receptor according to (aa) or the receptors according to (ab) specifically bind / bind an antigen which, at least in part of the mammals after the intestinal passage, has a structure which corresponds to the native structure or the structure against which a mammal after infection or immunization with the acid-resistant microorganism or an extract or lysate thereof or a protein thereof or a protein Fragment thereof or a synthetic peptide antibody produced; and (b) detects the formation of at least one antigen-receptor complex according to (a
  • the invention is also based on the idea of providing an immunochromatographic rapid test, such as a test strip, which is suitable for providing evidence of the infection mentioned.
  • the rapid chair test comprises several layers or areas, which preferably consist of possibly different porous materials.
  • the test strip has a sample application area, the actual test carrier (test or analysis area), and an absorber layer (absorption area).
  • the multiple layers or areas are firmly arranged on a polyester carrier.
  • the specific immunological receptors required for the detection or, more preferably, specific antibodies for the antigen are in a dried state. These are preferably with visibly colored particles, e.g. colloidal gold or polystyrene (latex) etc., marked.
  • the test carrier further preferably consists of a special test membrane such as nitrocellulose. Further specific receptors, which are directed against the antigen, are particularly preferred on this test membrane as the test line immobilized. A further interception line, for example receptors or antibodies directed against the labeled receptor or antibody, can be immobilized on the test membrane as a function check.
  • An absorber layer at the end of the test strip advantageously ensures that the sample flow, which is based on the capillary action of the porous materials in contact with one another, is maintained.
  • a labeled first specific receptor for the analyte or the antigen for example a labeled antibody (antibody conjugate)
  • a second specific receptor for the analyte or antigen is immobilized as a test line.
  • the first specific receptor such as an antibody conjugate
  • the first specific receptor is dissolved in the sample liquid and transported across the test membrane.
  • complexes of labeled first receptor or antibody conjugate and antigen or analyte form during the test run.
  • this complex binds to the second specific receptor and forms the so-called sandwich complex there.
  • the associated accumulation of the labeled receptors or antibody conjugates on the test line produces a visible test signal. If there is no analyte or antigen in the sample, no sandwich complex is formed and there is no signal formation.
  • streptavidin is immobilized on the test line instead of a specific receptor.
  • the specific receptor for the antigen used in the simple sandwich method as a catcher on the test line is conjugated to biotin and deposited together with a labeled specific receptor in the sample application area of the test strip.
  • the marking is colloidal gold.
  • the gold-labeled specific receptor is deposited in a first conjugate area of the sample application area of the test strip and the biotin-labeled specific receptor is deposited in a second conjugate area of the sample application area.
  • the labeled first specific receptor can be replaced by an unlabelled first specific receptor, for example antibodies. This first specific receptor is then detected by a further labeled receptor that binds this first specific receptor, the further labeled receptor not binding the second specific receptor, which is immobilized as a test line.
  • the specific second receptor immobilized on the test line can be replaced by a non-immobilized second specific receptor, for example antibodies.
  • the analyte-receptor complex is then bound by a receptor immobilized on the test line, which binds this non-immobilized second specific receptor, the further immobilized receptor not binding the first labeled specific receptor.
  • the non-immobilized second specific receptor is present bound to the receptor immobilized on the test line.
  • the first and second specific antibodies coming from different species.
  • the first specific unlabeled receptor is a mouse antibody
  • the second specific receptor is a rabbit antibody
  • the further labeled receptor is an anti-mouse antibody.
  • the specific non-labeled receptor is deposited in a first conjugate area of the sample application area of the test strip and the labeled receptor that binds the specific unlabeled receptor is deposited in a second conjugate area of the sample application area of the test strip.
  • the first conjugate area is arranged in the flow direction before or above the second conjugate area in the sample application area.
  • An immunochromatographic rapid test is particularly suitable for realizing the present invention.
  • This test is a dry reagent test, all of the specific reagents required for the analysis being contained in a test strip composed of several porous materials, preferably in the dried state.
  • Such a test is based on the principle that the analysis is started by adding a liquid sample and the sample liquid migrates due to capillary forces through a test strip composed of several porous materials. During the migration of the sample liquid, specific binding reagents are released and a complexation takes place between the analyte contained in the sample and specific binding reagents.
  • the complexes of analyte and specific binding reagents are captured in a defined zone, which is preferably designed as a test line, by specific binding reagent immobilized at this test site. These trapped complexes are caused by the accumulation of the visible particles coupled to the binding reagents, e.g. B. colored polystyrene (latex), colloidal gold, etc. made visible.
  • the test according to the invention is thus also feasible for non-specialists. Moreover it enables simple and hygienic handling. In the particularly preferred embodiments, only one step is required for carrying out the process, namely the application of a sample. The visually evaluable result is then available very quickly within a few minutes (2-30 minutes).
  • the immunochromatographic rapid test according to the invention is used in the test device described in WO98 / 58587. This combination enables quick and easy sample acquisition, preparation and analysis.
  • the rapid test according to the invention avoids the previously existing disadvantage in the analysis of stool samples that the sample dissolved in the buffer has a high content of solids which prevent or complicate the sample flow through the fine porous materials of the test strip.
  • the disadvantages in the prior art that stool samples must be greatly diluted can be avoided.
  • the stool samples diluted in the range from 1: 5 to 1:20 do not have to be centrifuged before the test and freed from larger solid components.
  • the present invention enables a highly sensitive test to be used for laboratory-independent use.
  • acid-resistant microorganism in the sense of this invention encompasses any microorganism which, because of its properties / adaptation mechanisms on the host resists the physical and chemical influences of the digestive tract, so that it can be detected by preferably immunological detection or using aptamers.
  • acid-resistant microorganisms are Helicobacter pylori, Helicobacter hepaticum, Mycobacterium tuberculosis, Mycobacterium pseudotuberculosis and Mycobacterium cansassii.
  • stool sample of the mammal means any stool sample which can be used for the detection method according to the invention.
  • this includes stool samples that have been prepared for diagnostic tests using known methods. The preparation is carried out, for example, according to the RIDASCREEN® Entamoeba enzyme immunoassay (R-Biopharm GmbH, Darmstadt).
  • the term "after the intestinal passage has a structure that corresponds to the native structure” means in the sense of this invention that the epitope of an antigen after the intestinal passage is recognized by a receptor, for example a monoclonal antibody, derivative or fragment thereof or the aptamer that / which was obtained against or binds to the same antigen / epitope that has not passed the intestinal passage.
  • a receptor for example a monoclonal antibody, derivative or fragment thereof or the aptamer that / which was obtained against or binds to the same antigen / epitope that has not passed the intestinal passage.
  • the epitope / antigen which is specifically bound by the above-mentioned receptor, survived the intestinal passage with regard to its structure without damage or essentially undamaged and has not been degraded.
  • a source of the native structure of the epitope / antigen can be, for example, a bacterial extract digested with a French press, which can be extracted using conventional methods (see, for example, Sambrook et al., "Molecular Cloning, A Laboratory Manual", 2nd edition 1989, CSH Press , Cold Spring Harbor, USA), or a bacterial lysate that was further purified using standard methods (eg Sambrook et al., Op. Cit.).
  • the term "after passage through the intestine has a structure which corresponds to the structure against which a mammal produces antibodies after infection or immunization with the acid-resistant microorganism or an extract or lysate thereof or a protein thereof or a fragment thereof or a synthetic peptide” means according to the invention that the epitope recognized by the receptor corresponds to an epitope which is presented by the immune system of a mammal, preferably a human.
  • the mechanisms of antigen presentation and mechanisms which lead to the processing of antigens and the resulting variety of antibodies are known in the prior art and are described, for example, in Janeway and Travers, Immunologie, 2nd edition 1997, Spektrum Akademischer Verlag GmbH, Heidelberg.
  • epitopes can differ from the native epitopes.
  • the mammal may come into contact with the microorganisms or the proteins or fragments or the synthetic peptides by natural infection (except for the synthetic peptides) or by immunization. Extracts, lysates, synthetic peptides etc. of the microorganism / protein can also be used for the immunization. suitable
  • Immunization schemes are known in the art and are described, for example, in Harlow and Lane, op. Cit. Suitable antibodies can also be obtained, for example, by immunization and / or screening for surrogates such as synthetic peptides, recombinantly produced proteins, extracts, lysates or partially digested proteins.
  • “Synthetic peptides” include those peptides that have at least one epitope of the native or intestinal-passed antigen.
  • the peptides can have the same primary structure as the antigen or fragments thereof. However, they can also have a different primary structure (primary amino acid sequence, eg conservative exchanges).
  • the term “specifically binds” means that the receptor has no or essentially no reactivity with other epitopes in samples from uninfected mammals. Typically, the receptor only binds to an epitope of an antigen that occurs in the stool sample.
  • the term “immune complex” encompasses complexes comprising monoclonal and / or polyclonal antibodies.
  • a prepared stool sample can be bound to a solid phase, for example via a capture receptor, and the infecting agent can be detected with the receptor present in the marked form.
  • the same receptor can be used both as a catcher and as a detector. It is also important for the method according to the invention that, for successful detection, only one epitope of an antigenic protein has to be detectable essentially consistently after passage through the intestine. This epitope can also occur several times on a homo dimer or multimer. However, the probability that this epitope can be found in a detectable form is much higher than if a detection test has to be based on more than one epitope to be detected.
  • a second embodiment must also be considered essential for the invention.
  • This embodiment relies on different receptors binding to different epitopes of the same antigen.
  • the term "essentially” means that the epitope (s) and thus a corresponding infection with the microorganism is more than 60 to 70%, preferably at least 75%, more preferably more than 85%, particularly preferably more than 90%, even more preferably more than 95% and most preferably more than 98% of those affected can be recorded. Ideally, infections are detected in 100% of those affected.
  • a relatively reliable diagnosis of the infection with these bacteria / pathogens can be carried out using a single receptor which specifically binds an epitope of an antigen of an acid-resistant microorganism or two receptors which specifically bind two epitopes of the same antigen .
  • the invention includes embodiments in which further epitopes, which have the aforementioned properties, of further receptors, e.g. of monoclonal antibodies or fragments or derivatives thereof or aptamers. The latter embodiments are suitable for increasing the reliability of the diagnosis even further.
  • These further receptors can advantageously be antibodies, fragments or derivatives which specifically recognize urease, preferably ⁇ -urease, the 26 kDa protein or Hsp 60, all preferably from H. pylori.
  • the detection of one or more of these proteins / protein fragments can be carried out in the same test and in an independent test with another part of the same sample.
  • H. pylori for example, it was found that main antigens in ELISA tests do not have the desired specificity and sensitivity; see. Newell et al., Serodiag. Immunother. Infect. Dis. 3 (1989), 1-6.
  • EP-A 0 806 667 teaches that reliable detection of H. pylori infections with receptors such as monoclonal antibodies is not possible due to the genetic variability of the H. py / or / ' strains.
  • the method according to the invention is particularly advantageous over the prior art mentioned because only one receptor enables a relatively reliable diagnosis.
  • Pairs of receptors such as antibodies, fragments, derivatives thereof or aptamers, are preferably used for the detection, for example in an ELISA or rapid test, the two The pair's receptors bind the same or different epitopes to the same antigen.
  • H. py / or / catalase forms multimeric structures from several identical subunits.
  • the same receptors can be used as capture receptors as well as detection receptors.
  • An increase in sensitivity and specificity can preferably be achieved by a combination of different mAbs which are directed against different epitopes of catalase or by a combination of two detection systems for different antigens (e.g. catalase / urease).
  • Another advantage of the method according to the invention is its design as a direct and non-invasive method, which increases the convenience mentioned above for the patient and the reliability in determining the stage of the disease.
  • Fig. 1 Cloned DNA sequence, one for the V region of the heavy chain
  • Catalase-specific monoclonal antibody (HP25.2m / 2H10).
  • Catalase-specific monoclonal antibody (HP25.2m / 2H10).
  • Catalase-specific monoclonal antibody (HP25.6m / 1 B5).
  • Catalase-specific monoclonal antibody (HP25.6m / 1 B5).
  • Fig. 6 Cloned DNA sequence coding for the V region of the heavy chain of a monoclonal antibody specific for ⁇ -urease.
  • Fig. 7 Cloned DNA sequence coding for the V region of the light chain of another monoclonal antibody specific for ⁇ -urease.
  • Fig. 8 Cloned DNA sequence coding for the V region of the heavy chain of another monoclonal antibody specific for ⁇ -urease.
  • Fig. 9 structure of a preferred test strip according to the invention.
  • sample application area (1, 2)
  • test area test membrane
  • absorption area (4)
  • the sample application area (1) consists of two superimposed conjugate areas.
  • the upper conjugate region or the conjugate fleece preferably contains the specific receptor, for example marked with gold.
  • the underlying conjugate area or the conjugate fleece (not shown) contains, for example, the biotin-labeled specific receptor.
  • a good sample flow and an even distribution of the immunoreagents in the sample suspension during the test procedure are of great importance for the sensitivity of an immunochromatographic rapid test. Both parameters are primarily influenced by the properties of the porous materials used, as well as their dimensions and mutual arrangement.
  • the sample application area of the test is composed of a conjugate fleece (1) and a subsequent filter (2).
  • the filter removes the solids in the stool suspension, which would prevent sample flow across the test membrane.
  • the test membranes with which a high sensitivity can be achieved, show a distribution of the pore sizes in the area between 2 and 20 ⁇ m, preferably 5 ⁇ m.
  • the filter has an exclusion size of 1-2 ⁇ m. Materials made of glass fiber or polyester-glass fiber mixtures are particularly suitable for this. Mixtures of natural and synthetic fibers developed for blood separation are also suitable.
  • the following filters are suitable, for example: Whatman GF / A, GF / B, GF / C, GF / D, F145, F147, F487, GF / DVA; Ahlstrom 111, 141, 142, 151, 164; Pall A / B, A / C, A / D, A / E, A / F.
  • the conjugate fleece serves, in addition to its function as a conjugate carrier layer, as a prefilter, which retains coarse solids in the suspended stool sample before it hits the filter. It is also advantageous with this structure that sample liquid and dissolved conjugate flow together through the downstream filter and thus the incubation time of analyte or antigen and conjugate is extended.
  • the dimensions of the conjugate fleece, filter and test membrane and the transitions between the materials of the sample application area are designed in such a way that sufficient filtering of the stool suspension is achieved.
  • the sample liquid may only come into contact with the conjugate fleece, but not with the filter.
  • the construction according to the invention ensures that a sufficient filter surface can come into contact with the sample liquid flowing through the conjugate fleece. Furthermore, the construction according to the invention enables a minimum distance between the conjugate fleece and the test membrane in order to rule out the passage of insufficiently filtered sample liquid onto the test membrane.
  • the dimensions of the individual areas or materials correspond to the following information:
  • the preferred width of the test strip is between 3 mm and 10 mm, particularly preferably 5 mm.
  • the preferred length of the test strip is 50-100 mm, particularly preferably 75 mm.
  • the preferred length of the conjugate fleece is in the range of 5-30 mm, particularly preferably 25 mm.
  • the overlap of conjugate fleece and filter is preferably between 5 and 15 mm, particularly preferably 10 mm. Filters of length between 10 and 20 mm are preferred, particularly preferably 15 mm.
  • the overlap between the filter and the test membrane is preferably between 1 and 3 mm, particularly preferably 1 mm.
  • the absorber layer at the end of the test strip (4) has both a sufficient capacity for holding the sample liquid which has migrated through the test strip and a relatively fine-pored structure for maintaining the capillary action.
  • Cellulose-glass fiber materials such as Whatman 17 CHR, 3 MM, 31 ET, WF1.5, D28, CD 427-05, CD 427-07, CD 427-08 have proven particularly suitable for this purpose; Schleicher & Schuell 2992, GB 003, GB 004; Pall 111, 113, 133, 165, 197; Ahlstrom 320, 222, 238, 237.
  • Particularly preferred for test strips with a width of 5 mm is a dimension of 10-30 mm in length for the analysis area.
  • the overlap of the test membrane on the absorber layer is preferably at least 1 mm.
  • the rapid test of the invention is particularly preferably used in a device for recording and examining samples, as described in WO 98/58587 (PCT / EP98 / 03764).
  • PCT / EP98 / 03764 PCT / EP98 / 03764
  • the acid-resistant microorganism is an acid-resistant bacterium.
  • the acid-resistant bacterium a bacterium of the genus Helicobacter, Campylobacter or the genus Mycobacterium.
  • the bacterium is a bacterium of the species Helicobacter pylori, Helicobacter hepaticum, Campylobacter jejuni or a bacterium of the species Mycobacterium tuberculosis.
  • the receptor (s) are (an) antibody, (a) fragment (s) or (a) derivative (s) thereof or (a) aptamer (s).
  • receptor also includes further binding partners such as, for example, avidin, streptavidin or polystreptavidin and biotin.
  • fragments or derivatives of monoclonal antibodies have the same binding specificity as the monoclonal antibodies.
  • fragments or derivatives can be produced by customary methods; see. eg Harlow and Lane “Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, USA, 1988.
  • fragments are Fab, F (ab ') 2 or Fv fragments.
  • derivatives are scFv fragments.
  • Derivatives can also be chemically produced substances that have the same or improved binding properties as the antibodies. Such substances can be produced, for example, by peptidomimetics or by various rounds of phage display and subsequent selection for improved binding properties.
  • aptamer is known in the prior art and is defined, for example, in Osborne et al., Curr. Opin. Chem. Biol. 1 (1997), 5-9, or in Stull and Szoka, Pharm. Res. 12 (1995), 465-483.
  • the term "antigen-antibody complex” in the sense of this invention includes not only complexes which the antigen enters into with the native antibody, but also complexes which it enters into with its fragments or derivatives.
  • the invention encompasses embodiments in which only monoclonal antibodies or fragments or derivatives thereof or only aptamers are used, as well as embodiments in which different types of detection reagents are used in a test. It is thus possible for a first monoclonal antibody with a second antibody derivative or a first aptamer with a second antibody fragment to be used, to name just two examples. In this respect, the terms “first” and “second” designate the first and second detection reagents. This does not mean that two antibodies, derivatives or fragments thereof or two aptamers are always used.
  • the antigen is the antigen of a catalase.
  • the catalase has the particular advantage that it could be detected in all acid-resistant bacteria known to date. According to the invention, it could be determined as a further advantage that the catalase is very resistant to digestion in the intestinal tract, which simplifies the detection of significant amounts. Finally, the catalase or fragments thereof are often still of a higher order after the intestinal passage, for example in tetrameric form, which facilitates detection with only one type of receptor.
  • the catalase is the catalase from H. pylori.
  • the antigen is a metalloproteinase, particularly preferably the H. pylori metalloproteinase.
  • the antigen is a urease, preferably from H. pylori.
  • a mixture of receptors is additionally used for the detection, the mixture of receptors acting as a catcher of the antigen if the receptor is used as a detector of the antigen and the mixture functioning as a detector of the antigen if the receptor is a catcher of the antigen is used.
  • different mixtures of receptors can be used as scavengers and detectors of the antigen as well as the same mixture as scavengers and detectors of the antigen.
  • the catcher is preferably in a marked form and the detector is immobilized on the test line.
  • This embodiment of the invention allows a particularly reliable diagnosis, especially if the antigen is not in dimeric or multimeric conformation after passage through the intestine.
  • This embodiment allows only one of the two types of receptors used in most standardized immunological detection methods to be a monoclonal antibody, while for example the second type of receptor can be a polyclonal serum.
  • the mixture of receptors is a polyclonal antiserum.
  • mixtures of receptors are used for the detection, a mixture of receptors acting as a scavenger of the antigen and a mixture of receptors functioning as a detector of the antigen and preferably at least one mixture being a polyclonal serum.
  • a mixture of receptors acts both as a catcher and as a detector of the antigen, this mixture preferably being a polyclonal antiserum.
  • the polyclonal antiserum was obtained against a lysate of the microorganism, preferably H. pylori.
  • the lysate is a lysate with enriched antigen.
  • the lysate is a depleted immunodominant antigen lysate.
  • the aforementioned two embodiments also include that the lysate is a lysate with enriched antigen, preferably with enriched catalase as well as with depleted immunodominant antigen, preferably main antigenic urease.
  • the combination mentioned leaves a good and particularly suitable for the method according to the invention Immunization yield too.
  • One way of carrying out corresponding enrichment or depletion processes is described in more detail in the examples.
  • the polyclonal antiserum was obtained against a purified or a (semi) synthetically produced antigen, which is preferably a catalase, metalloproteinase or urease enzyme, preferably from H. pylori.
  • the receptors preferably the monoclonal antibodies, fragments or derivatives thereof or the aptamers, can recognize and specifically bind linear or conformation epitopes. In a further preferred embodiment, at least one of the receptors binds a conformation epitope.
  • all receptors bind conformation epitopes.
  • the heavy chain has the
  • Catalase epitope binding antibody [HP25.2m / 2H10] at least one of the following CDRs, preferably the CDR3 and more preferably all three of the following
  • the DNA sequence encoding the catalase epitope-binding antibody [HP25.2m / 2H10] has at least one of the following CDRs, preferably CDR3 and more preferably all three of the following CDRs: CDR1: AACTACTGGATTCAC CDR2: TACATTAATC CTGCCACTGG TTCCACTTCT TACAATCAGG
  • the light chain of the antibody [HP25.2m / 2H10] binding a catalase epitope has at least one of the following CDRs, preferably the CDR3 and more preferably all three of the following CDRs: CDR1: SASSSVNYMY
  • the DNA sequence encoding the light chain of the antibody [HP25.2m / 2H10] binding a catalase epitope has at least one of the following CDRs, preferably CDR3 and more preferably all three of the following CDRs: CDR1: AGTGCCAGCT CAAGTGTAAA TTACATGTAC
  • CDR3 CAGCAGTGGA GTAGTAATCC GTACACG
  • the heavy chain of the antibody [HP25.6m / 1 B5] binding a catalase epitope has at least one of the following CDRs, preferably CDR3 and more preferably all three of the following CDRs:
  • the DNA sequence encoding the heavy chain of the antibody [HP25.6m / 1 B5] binding a catalase epitope has at least one of the following CDRs, preferably CDR3 and more preferably all three of the following CDRs: CDR1: GACACCTATGTGCAC
  • CDR2 AAGATTGATCCTGCGAATGGTAAAACTAAATATGACCCGATATTC
  • the light chain of the antibody [HP25.6m / 1 B5] binding a catalase epitope has at least one of the following CDRs, preferably CDR3 and more preferably all three of the following CDRs:
  • DNA sequence at least one of the following CDRs, preferably the CDR3 and more preferably all three of the following CDRs:
  • the ß-urease-specific antibody is that of one of the hybridomas HP8m deposited with the German Collection of Microorganisms and Cell Cultures (DSMZ) on June 23, 1998 according to the statutes of the Budapest Treaty under the deposit numbers DSM ACC2360 or DSM ACC2362 / 4H5-D4-C9 or HP9.1 m / 3C2-F8-E2 produced antibodies.
  • the ⁇ -urease-specific antibody HP8m / 1 H5-G2-B4 described in the figures is produced by a daughter clone of the deposited hybridoma HP8m / 4H5-D4-C9.
  • the two antibodies produced by the mother and daughter clones are encoded by identical DNA sequences and have the same properties.
  • the heavy chain of the antibody binding an epitope of the ⁇ -urease has at least one of the following CDRs, preferably CDR3 and more preferably all three of the following CDRs:
  • CDR1 GFTFSSHFMS
  • CDR2 SISSGGDSFYPDSLKG
  • CDR3 DYSWYALDY or:
  • the DNA sequence coding the epitope of the ⁇ -urease-binding antibody has at least one of the following CDRs, preferably CDR3 and more preferably all three of the following CDRs:
  • CDR1 GG CTACGCATTC AGTACCTCCT GGATGAAC
  • CDR2 CGGATTTATC CTGGAGATGG AGATACTAAC TACAATGGGA
  • CDR3 GAG GATGCCTATT ATAGTAACCC CTATAGTTTG GACTAC or:
  • CDR2 TCCATTAGTA GTGGTGGTGA CAGTTTCTAT CCAGACAGTC TGAAGGGC
  • the light chain of the antibody binding an epitope of the ⁇ -urease has at least one of the following CDRs, preferably CDR3 and more preferably all three of the following CDRs:
  • CDR3 QQSNTWPLT or:
  • DNA sequence encoding the light chain of this antibody preferably has the following CDRs:
  • CDR1 A GGGCCAGTCA GAGCATTGGC ACAAGAATAC AC
  • CDR2 TAT GGTTCTGAGT CTATCTCT
  • CDR3 CAACAA AGTAATACCT GGCCGCTCAC G or:
  • CDR1 C ATGCCAGTCA GAACATTAAT GTTTGGTTAA GC
  • CDR2 AAG GCTTCCAACT TGCACACA
  • CDR3 CAACAG GGTCGAAGTT ATCCTCTCAC G
  • the heavy and light chains which have the CDRs indicated above occur together in an antibody, fragment or derivative thereof, the catalase or the ⁇ -urease or a fragment thereof, preferably from H. specifically binds pylori.
  • the invention also encompasses embodiments in which these heavy or light chains are combined with other light or heavy chains, whereby the binding properties can essentially be maintained or improved.
  • Corresponding methods are known in the prior art.
  • Particularly preferred antibodies in the variable regions of the light and heavy chains have those shown in FIGS. 1 and 2, 3 and 4, 5 and 6 or 7 and 8 or the regions are encoded by the DNA sequences shown there.
  • the CDRs can be integrated into various FRs (“framework regions”) using methods known in the prior art.
  • the following steps are carried out with the stool sample before incubation with the antibodies:
  • the stool sample is suspended 1: 3 to 1:25, preferably about 1:15 in a sample buffer.
  • sample buffers are known in the prior art.
  • An exemplary sample buffer contains 150 mM PBS, 0.1% SDS.
  • the sample buffer consists of 150 mM PBS, 0.5% serum and 2% detergent.
  • the serum can be obtained from cattle, mouse, rat, pig or human and the detergent can be selected from the group of ionic (preferably Tween 20) or non-ionic detergents (preferably SDS).
  • the detection according to the invention can also be used for the detection of H. pylori in gastric gases, breath condensate, saliva, tooth plaque, mucosal smears, biopsies, whole blood or serum.
  • Breathing gases can be obtained by administering cold CO 2 -containing beverages to the patient, which cause gastric gases to be released in the form of “belches”.
  • gases can be collected in suitable containers or obtained in accordance with breathing condensate in a manner known to the person skilled in the art, for example by means of a device according to DE 19718925 or a device according to DE 19505504.
  • the condensates obtained in this way can then be introduced into the test according to the invention in liquid form, wherein all steps of the method according to the invention are as described above, with the exception that a sample as described here is used instead of a stool sample.
  • Dental plaque and mucosal smears are obtained according to the methods known in the prior art and can be used in the detection according to the invention like saliva, whole blood and serum in a suitable concentration and modification of the resuspending buffer.
  • the formation of the at least one antigen-receptor complex / antigen-receptor is detected. / Receptor mixture complex in step (b) by means of an immunochromatographic method.
  • the same receptor is used in the immunological method for binding to the solid phase and for detecting the epitope.
  • the capture receptor can be bound in an unmodified form to a solid phase, for example nitrocellulose, the receptor used for the detection is optionally provided with a label.
  • the capture receptor can be in biotinylated form and can be bound to it by streptavidin immobilized on the solid phase.
  • the catcher receptor can not be biotin-labeled and the epitope of the microorganism, preferably the bacterial epitope, can be detected via a third biotin-labeled receptor, which receptor is preferably an antibody, fragment or derivative thereof or an aptamer, or a species-specific or Ig class-specific antibody or a corresponding aptamer.
  • This third biotin-labeled receptor specifically binds the capture receptor, and the analyte-receptor complex is bound to the test line, which in this embodiment consists of immobilized streptavidin, via the third biotin-labeled receptor.
  • Colloidal gold, selenium, colored polystyrene or latex particles, carbon particles and (known to the person skilled in the art) disperse colors can be used as a marker for the receptor used for detection.
  • the receptor used for the detection can also not be labeled and thus the epitope of the microorganism can also be detected via a third labeled receptor, which acts against is directed to this unlabeled receptor, this receptor preferably being an antibody, fragment or derivative thereof or an aptamer that can be a species-specific or Ig-class-specific antibody or a corresponding aptamer.
  • the marking is colloidal gold.
  • Such markings are known in the prior art; see. for example Harlow and Lane op.
  • the embodiment described above is particularly favorable for the detection of catalase, which may also be present as a tetramer even after passage through the intestine.
  • combinations of antibodies, fragments, derivatives and aptamers can also be used in this embodiment, e.g. Combinations of antibodies etc. that bind to different epitopes of the same antigen.
  • the monoclonal antibody is a mouse antibody.
  • the receptors are fixed to a support.
  • the fixation of the receptors, preferably the antibodies, fragments or derivatives thereof or the aptamers to a support is particularly advantageous for carrying out routine checks.
  • the combination of antibody carrier / aptamer carrier can also be packaged well as a test kit or in kit form.
  • the carrier material is a porous carrier material.
  • the carrier material is a test strip.
  • the carrier material consists of cellulose or a cellulose derivative.
  • the mammal whose stool, gastric gas, breath condensate, saliva, dental plaque, mucosal swab, biopsy, whole blood or serum can be examined with the method according to the invention, can be an animal, for example a pet such as a cat or a dog, a farm animal, e.g. be a pig or other animal such as a mouse, a tiger, a gerbil or a ferret.
  • a pet such as a cat or a dog
  • a farm animal e.g. be a pig or other animal such as a mouse, a tiger, a gerbil or a ferret.
  • the mammal is a human.
  • the method according to the invention is an automated method.
  • An automated method can be carried out, for example, by means of a robot, the robot carrying out part or all of the method steps.
  • Corresponding robots are known in the prior art.
  • the invention relates to a monoclonal antibody, a fragment or derivative thereof which has a V region which has a combination of the CDRs shown above or which is produced by one of the hybridomas shown above.
  • Monoclonal antibodies, fragments or derivatives thereof are preferred which have at least one of the V regions shown in FIGS. 1 and 2, 3 and 4, 5 and 6 or 7 and 8. These antibodies preferably have two of the V regions shown in FIGS. 1 and 2, 3 and 4, 5 and 6 or 7 and 8. It is also preferred that these V regions are encoded by the DNA sequences shown in FIGS. 1 and 2, 3 and 4, 5 and 6 or 7 and 8.
  • the monoclonal antibody, the fragment or derivative thereof is a mouse antibody or a fragment or derivative thereof or a chimeric, preferably a humanized antibody or a fragment or derivative thereof.
  • the derivative can also be a fusion protein.
  • the antibody is labeled, for example with a colloid, with a label consisting of gold, selenium, latex, colored polystyrene, carbon particles, disperse colors known to the person skilled in the art.
  • the invention also relates to an aptamer that specifically binds the same epitope as the monoclonal antibody, fragment or derivative thereof.
  • aptamers can be prepared using methods known in the art.
  • the invention further relates to an epitope which is specifically bound by one of the monoclonal antibodies, fragment or derivative thereof or aptamer described above.
  • the invention relates to further antibodies, derivatives or fragments thereof which specifically bind the epitope according to the invention.
  • These antibodies can be, for example, monoclonal antibodies, which can be produced using the epitope as a hapten / component of an antigen by conventional methods.
  • the present invention further relates to a diagnostic composition containing at least one receptor, preferably at least one monoclonal antibody, fragments or derivatives thereof or aptamers as defined above, fixed to a carrier material. Furthermore, the present invention relates to a test device for the detection of at least one epitope as defined above, comprising (a) at least one receptor, which is preferably a monoclonal antibody, fragments or derivatives thereof or an aptamer as defined above, fixed to a support material; (b) a device for processing and analyzing stool samples; and optionally (c) a mixture of receptors as defined above.
  • the invention further relates to a device for the preparation and analysis of stool samples as described in WO 98/58587.
  • This device contains the sample collection, preparation and test unit (test strips) in one device.
  • the invention further relates to a test device comprising (a) at least one receptor, preferably a monoclonal antibody, fragments or derivatives thereof or an aptamer as defined above, the receptor being conjugated to colloidal gold, polystyrene (latex) or other color-imparting particles , the size of which is typically in the range between 5 nm and 100 nm, preferably between 40 nm and 60 nm (particularly preferred is the particle size from 40 nm to 60 nm for gold and a particle size from 200 nm and 500 nm for latex); (b) a device for the preparation and analysis of stool samples, as described for example in WO 98/58587; and optionally (c) a mixture of receptors as defined above.
  • a test device comprising (a) at least one receptor, preferably a monoclonal antibody, fragments or derivatives thereof or an aptamer as defined above, the receptor being conjugated to colloidal gold, polystyrene (latex) or other
  • compositions and kits can also have devices for processing (if necessary) and analyzing gastric gases, breathing condensate, saliva, dental plaque, mucosal swabs, biopsies, whole blood or serum.
  • the present invention relates to a kit containing (a) at least one receptor, which is preferably a monoclonal antibody, Fragments or derivatives thereof or an aptamer as defined above, fixed to a support material; optionally further (b) a device for the preparation and analysis of stool samples as described for example in WO 98/58587; and optionally (c) a mixture of receptors as defined above.
  • a receptor which is preferably a monoclonal antibody, Fragments or derivatives thereof or an aptamer as defined above
  • Figure 1 Cloned DNA sequence encoding the heavy chain V region of a catalase specific monoclonal antibody [HP25.2m / 2H10]. The encoded amino acid sequence is shown in the one-letter code. According to Kabat et al. certain CDR regions 1-3 are highlighted by underlining.
  • Figure 2 Cloned DNA sequence encoding the light chain V region of a catalase specific monoclonal antibody [HP25.2m / 2H10].
  • the encoded amino acid sequence is shown in the one-letter code. According to Kabat et al. certain CDR regions 1-3 are highlighted by underlining.
  • Fig. 4 Cloned DNA sequence coding for the V region of the light chain of a monoclonal antibody [HP25.6m / 1 B5] specific for catalase. The encoded amino acid sequence is shown in the one-letter code. According to Kabat et al. certain CDR regions 1-3 are highlighted by underlining.
  • Fig. 5 DNA sequence coding for a light chain of a first urease-specific monoclonal antibody (DMS ACC2360). The encoded amino acid sequence is also shown in the one-letter code. According to Kabat et al. certain CDR regions 1-3 are highlighted by framing.
  • Figure 7 DNA sequence encoding a light chain of a second urease specific monoclonal (DMS ACC2362).
  • the encoded amino acid sequence is also shown in the one-letter code. According to Kabat et al. certain CDR regions 1-3 are highlighted by framing.
  • Fig. 8 DNA sequence coding for a heavy chain of a second urease-specific monoclonal antibody (DMS ACC2362). The encoded amino acid sequence is also shown in the one-letter code. According to Kabat et al. certain CDR regions 1-3 are highlighted by framing.
  • Fig. 9 General structure of the rapid test strip: sample application area (1); Test or analysis area (3) and absorption area (4).
  • the receptors required for the detection such as specific antibodies for the analyte or the antigen, which are marked with visible colored particles, for example colloidal gold or polystyrene (latex), or other binding partners, are in the dried state.
  • the Test carriers usually consist of a special test membrane such as nitrocellulose. Further specific receptors, which are directed against the analyte or the antigen, are immobilized as a test line on this test membrane.
  • sample application area (1); Test or analysis area (3) and absorption area (4).
  • the receptors for the antigen required for the detection which are coated with visibly colored particles, e.g. colloidal gold or polystyrene.
  • the sample application area can consist of two superimposed conjugate areas which contain, for example, the gold-labeled receptor in one area and a biotin-labeled receptor in the other.
  • the test carrier usually consists of a special test membrane such as Nitrocellulose. Further specific receptors, which are directed against the analyte (antigen), are immobilized on this test membrane as test line (6).
  • streptavidin can be immobilized as the test line.
  • a further control or interception line (7) for example a receptor directed against the labeled receptor, can be immobilized on the test membrane as a functional check.
  • Example 1 Isolation of H. pylori antigens
  • H. pylori strain NCTC 11637 was streaked in Petri dishes on Wilkins-chalk agar with the addition of 10% horse blood and amphotericin B, vancomycin and cefsoludin (Sigma Chemicals) and 1-2 days under a microaerophilic atmosphere (Anaerocult GasPAk, Merck) incubated at 37 ° C.
  • the content of 2 Bowls were suspended in 350 ml of BHIB medium with the addition of antibiotics as above in a 1 liter bottle (Schott), the medium was gassed for 4-8 min with a gas mixture of 10% CO 2 , 5% O 2 , 85% N 2 and closed the bottle.
  • the culture was shaken on a rotary shaker at 37 ° C for 2 days.
  • the contents of the bottle were then transferred sterile into a 10 liter bottle and filled up with 4.7 liter BHIB medium.
  • the bottle was then incubated for a further 2 days at 37 ° C on a rotary shaker.
  • the entire volume was then centrifuged at 5000 g for 15 min, the supernatant decanted and the bacterial pellet weighed.
  • the pellet was resuspended in a physiological saline solution with the addition of 15% glycerol in a ratio of 2: 1 (w / v) and frozen at -80 ° C.
  • a microscopic inspection of the bacteria and tests for urease, oxidase and catalase activity were carried out.
  • H. pylori bacterial pellet (Example 1) was added 1:10 with PBS, pH 7.5 and resuspended on ice.
  • the bacterial cells were sonicated on ice with the small probe of an ultrasound device (Sonifier, Branson), at 25-30% intensity 10 x 60 s with a pause of 60 s each.
  • the digested bacterial cells were centrifuged 2 x 20 min, at 4 ° C and 10,000 rpm (Sorvall, SS-34). The supernatant was used as an antigen preparation for the production of polyclonal antisera.
  • Frozen bacterial pellet was mixed 1: 2 (w / v) with digestion buffer (20 mM Tris / HCl pH 7.0, 1 mM EDTA, 1 mM phenyl-methyl-sulfonyl-fluoride (PMSF), 0.05% sodium azide and 10 % (v / v) isobutanol) and shaken at room temperature (RT) on an overhead mixer until thawing is complete and additionally shaken for a further approx. 15 min. After centrifugation at 20,000 RPM (Sorvall SS34), 4 ° C for 20 min, the supernatant was decanted off and filtered through a 0.45 ⁇ m filter.
  • digestion buffer (20 mM Tris / HCl pH 7.0, 1 mM EDTA, 1 mM phenyl-methyl-sulfonyl-fluoride (PMSF), 0.05% sodium azide and 10 % (v / v) isobutanol
  • the clear supernatant was diluted 1: 3 with buffer A (20 mM Tris HCl pH 7.0, 1 mM EDTA, 1 mM PMSF, 0.05% sodium azide) and onto a SourceQ column (16/10) equilibrated with buffer A. (Pharmacia) transferred.
  • the pass from the SourceQ column contained the enzyme catalase and was free of H. pylori major antigens such as urease, HSP60 and alkyl hydroperoxide reductase.
  • H. pylori major antigens such as urease, HSP60 and alkyl hydroperoxide reductase.
  • To isolate the catalase the run from the SourceQ column was subjected to molecular sieve chromatography (Superdex 200) (16/60). The catalase was isolated together with another approximately 150 kDa protein (neutrophil activating protein, NAP) in approximately equal proportions.
  • Catalase was obtained in higher purity when the run from the SourceQ column was brought to 40 mM sodium acetate with a 2 M sodium acetate solution, pH 4.9 and transferred to a SourceS column (8/28). After a washing step with buffer A to remove unbound proteins, the catalase was eluted with buffer B (40 mM sodium acetate, 1 M NaCl, pH 4.9) using a linear NaCI gradient (buffer A plus 0% to 100% buffer B). Catalase elutes at approximately 370 mM NaCI.
  • the purified protein had a molecular weight of approx. 58 kDa and a purity of> 90% under reducing conditions in SDS-PAGE.
  • ERLHDTIGESLAHVTHK This sequence is identical to the corresponding LysC peptide from H. pylori catalase (Manos J. et al. (1998) Helicobacter 3 (1), 28-38; Genbank Accession No AAC16068.1)
  • a selected mammal eg mouse, rabbit, goat, etc.
  • the antibodies can be purified from sera by means of protein A affinity chromatography and used as capture antibodies in the sandwich ELISA (see Example 8) to assess the suitability of monoclonal antibodies for antigen detection in a patient's chair.
  • Polyclonal rabbit antisera were produced by pab Productions (Herbertshausen) from H. py / or / ' lysate. From these antisera, polyclonal antibodies were purified by means of protein A affinity chromatography and used as capture antibodies in the sandwich ELISA (see Example 8) to assess the suitability of monclonal antibodies for the detection of H. py / or / ' antigens in a patient 's chair. Production of monoclonal antibodies:
  • Monoclonal antibodies were produced by methods known to those skilled in the art (Harlow & Lane, 1988; Peters & Baumgarten, 1990).
  • Antigen preparations made from H. py / or / ' lysate were used to immunize mice (BALB / cx C57 / Black, F1 generation, 8-12 weeks old).
  • 50 ⁇ g of antigen were emulsified 1: 1 with complete Freund's adjuvant (Difco) and injected intraperitoneally (200 ⁇ l / mouse).
  • the mice each received 25 ⁇ g antigen with incomplete Freund's adjuvant.
  • Antiserum was obtained from retroorbitally drawn blood as a positive control in the ELISA (see fusion screening).
  • the spleens were removed from the mice and the spleen cells were fused with the myeloma cells P3x63Ag8.653 (ATCC CRL-1580; Kearney et al., 1979) in a 5: 1 ratio with polyethylene glycol 4000.
  • the hybridomas were cultivated at 37 ° C., 5% CO 2 and 95% relative atmospheric humidity.
  • the antibody-containing culture supernatants from overgrown wells were screened in a direct ELISA on 96-well microtiter plates (MaxiSorb, Nunc): The ELISA plates were coated with 2 ⁇ g / ml immunization antigen in carbonate buffer, pH 9.6 (100 ⁇ l / well, overnight, 5 ° C.). The coating solution was suctioned off and free binding sites were blocked with 2% skim milk powder in PBS (w / v) (200 ⁇ l / well 1 h, room temperature).
  • the culture supernatants of the primary clones were pipetted undiluted into the wells (100 ⁇ l / well) and the plates were incubated for 1 to 2 hours at room temperature. Antiserum was used as the positive control and medium as the negative control. After washing again, the bound antibodies were detected with a peroxidase-labeled secondary antibody (rabbit anti-mouse Ig-POD (DAKO) in PBS with 0.1% bovine serum albumin, 20 min, room temperature). After washing the plate four times, substrate solution (K-Blue, Neogen or citric acid buffer, pH 4.5 with TMB + H 2 O 2 ) was added.
  • substrate solution K-Blue, Neogen or citric acid buffer, pH 4.5 with TMB + H 2 O 2
  • the peroxidase converts the colorless substrate tetramethylbenzidine (TMB, Sigma) into a colored complex. After 10 minutes the reaction was stopped by adding 1N sulfuric acid. Culture supernatants from clones that produce antigen-specific antibodies showed a clear coloration compared to the colorless negative culture supernatants.
  • the culture supernatants were checked in western emblot for the ability to specifically recognize the immunization antigen.
  • 15 g of purified antigen per gel were boiled in reducing sample buffer (Laemmli, 1970) and applied to a 12% SDS-poplyacrylamide mini gel (8.6 cm x 7.7 cm x 0.1 cm, Biometra). After electrophoretic separation at 25-30 mA, the proteins (antigen) were immobilized on a nitrocellulose membrane using the semidry blot method.
  • the membrane was blocked with 2% skim milk powder in PBS (30 min, room temperature) and washed three times for 5 min with TBS / Tween-20 (0.2%).
  • the membrane was clamped in an Accutran cross-blot screening unit (Schleicher and Schuell) using a grid plate with 34 cross channels. 250 ⁇ l of TBS / Tween-20 were placed in each of the resulting lanes and 250 ⁇ l of the hybridoma culture supernatants to be tested were added. The incubation was carried out for 2 hours at room temperature with shaking.
  • the membrane was incubated for 1 h with the POD-conjugated secondary antibody (rabbit anti-mouse Ig-POD, DAKO). The membrane was washed three times and the immune complex was visualized by adding the 3,3-diaminobenzidine substrate solution (DAß, Sigma). The antibody binding protein bands were then visualized through an insoluble peroxidase substrate.
  • POD-conjugated secondary antibody rabbit anti-mouse Ig-POD, DAKO
  • DAß 3,3-diaminobenzidine substrate solution
  • Example 6 Screening of mAb culture supernatants on patient samples (mixed polyclonal / monoclonal system)
  • Stool samples were available as internal development samples and their infection status (groups 0 and 4) was determined by histological examination and / or 13 C-urea breath test. Infection with H. pylori was safely ruled out in group 0 patients, and infection in group 4 patients was reliably detected.
  • the ELISA plates (MaxiSorb; Nunc) were coated overnight at 5 ° C. with 100 ⁇ l of a solution of a polyclonal rabbit anti-catalase antibody or polyclonal rabbit anti-H. py / or / ' antibody (pAk; approx. 20 ⁇ g IgG / ml 0.1 M carbonate buffer, pH 9.5).
  • pAk polyclonal rabbit anti-catalase antibody
  • polyclonal rabbit anti-H. py / or / ' antibody pAk; approx. 20 ⁇ g IgG / ml 0.1 M carbonate buffer, pH 9.5.
  • 200 ⁇ l of 150 mM PBS pH 7.2 with 0.2% fish gelatin (w / v) per well were added and incubated for 30 min at room temperature.
  • the ELISA plate was then washed twice with 250 ⁇ l PBS with the addition of 0.025% Tween-20 (washing buffer 1).
  • Human stool was suspended in a ratio of 1:10 (w / v) with 150 mM PBS with the addition of 2% skim milk powder and 1 mM EDTA.
  • 50 ng / ml catalase (see Example 2) was added to an H. pylori negative stool suspension and diluted with an H. pylori negative stool suspension in 1: 2 steps.
  • 100 ⁇ l of the stool suspension were incubated per well for one hour (double determination in patient samples).
  • the plate was washed 4 times with wash buffer 2 (PBS with 0.2% Tween-20).
  • 100 ⁇ l of culture supernatant from hybridomas were added and incubated for 60 min at RT.
  • the bound antibodies were detected by adding a conjugated secondary antibody (rabbit anti-mouse IgG-POD, DAKO, Copenhagen, Denmark).
  • the peroxidase (POD) converts the colorless substrate tetramethylbenzidine (TMB, Sigma) into a blue product.
  • TMB colorless substrate tetramethylbenzidine
  • the reaction was stopped by adding 1 N sulfuric acid (100 ⁇ l / well).
  • the strength of the color reaction was measured in the ELISA reader (MWG spectral). The measurement was carried out at 450 nm against the reference wavelength of 620 nm. Before adding the detection antibody or the substrate solution, the ELISA plate was washed 3-4 times with wash buffer 1.
  • the lowest concentration at which an absorbance greater than or equal to twice the control (H. pylori negative stool sample without antigen addition) was detected was set as the detection limit.
  • AK antibody
  • HP H. pylori
  • PAH polyclonal antibody The monoclonal antibody HP25.2m / 2H10 showed a sensitivity of 68% in a sandwich ELISA with patient samples (17 of 25 positive samples were correctly identified) and a specificity of 82% (of 17 samples, 14 were correctly recognized).
  • Ag antigen
  • WB western emblot
  • NWG detection limit
  • Table 2 summarizes the results of the isotype determination, the Westemblot analyzes, the detection limit determination and the patient recognition for the monoclonal antibodies in the culture supernatant against catalase.
  • the mAb HP25.2m / 2H10 shows a sensitivity of 68% and a specificity of 82%.
  • An improvement in sensitivity and specificity was shown by using purified mAb (instead of culture supernatant) in a purely monoclonal ELISA system.
  • Either a monoclonal antibody which is directed against the same epitope of the antigen or two different monoclonal antibodies which are directed against different epitopes of the same antigen can be used as capture and detector antibodies.
  • the purification of mAbs from serum-free hybridoma culture supernatants is carried out using modified Protein-G affinity chromatography (Pharmacia Biotech, 1994).
  • the filtered (0.45 ⁇ m) culture supernatants were passed directly over a Protein G matrix.
  • the protein detection in the run or eluate was carried out by measuring the optical density at 280 nm. After a washing step with 150 mM PBS, pH 7.2 until the detector background value was reached, 0.1 M glycine / HCl, pH 3, 3 eluted.
  • the protein G matrix was regenerated with 0.1 M glycine / HCl, pH 2.7.
  • Example 8 Characterization of the purified monoclonal antibodies and antibody selection for the test
  • the affinity constants of the monoclonal antibodies can be determined using SPR spectroscopy. This makes it possible to find suitable antibodies for the development of ELISA and rapid tests.
  • catalase-specific monoclonal antibodies By adding the catalase-specific monoclonal antibodies, they were reacted with immobilized catalase and the mass accumulation on the detector was measured. Antibody solutions of different concentrations in the range between 20 and 670 nM were used. These were injected at a flow rate of 25 ⁇ l / min each via the catalase immobilized on the sensor chip CM5.
  • the epitope mapping was carried out by Pepscan Systems (Netherlands). A peptide library (30-mer with an overlap of 27 amino acids) of the catalase was prepared on plastic cards and incubated with the antibodies. The determined epitopes (peptides to which antibodies have bound) are listed in Table 4. HP25.2m / 2H10 showed unspecific peptide recognition, which means that this antibody is very likely to bind to a discontinuous structural epitope. In addition to the main recognition region (see Table 4), HP25.6m / 1 B5 also showed other non-specific peptide bonds, which can be expected to involve a structural component. If one transfers the determined epitopes to the structure of E.
  • the ELISA plates (MaxiSorb; Nunc) were coated for 1 h at 37 ° C. with 100 ⁇ l of a mAb solution in carbonate buffer, 0.1 M, pH 9.5. To block the binding sites that were still free, 200 ⁇ l of 150 mM PBS with 0.2% fish gelatin (w / v) per well were pipetted and incubated for 30 minutes at room temperature. This was followed by two washes with 250 ⁇ l wash buffer 1 (PBS with 0.025% Tween). Human stool was 1:10 (w / v) with 150mM PBS with the addition of 2% Skimmed milk powder and 1 mM EDTA suspended. To determine the antigen detection limit, purified H.
  • py / or / ' catalysis was added in known concentrations to the stool suspension of an H. pylori negative patient (null stool).
  • the stool sample suspensions were centrifuged at 7000 g for 5 min. 100 ⁇ l of the supernatant were incubated for 1 h per well. The samples were plotted as duplicates.
  • the plate was then washed 4x with washing buffer 2 (250 ⁇ l PBS with the addition of 0.2% Tween). Then 100 ⁇ l of a solution was biotin-coupled in PBS; 0.1% BSA added and incubated for 60 min at RT.
  • the bound antigen / antibody complexes were detected by adding a conjugate of streptavidin with POD (Dianova).
  • the POD converts the colorless substrate TMB (Sigma) into a blue product.
  • the reaction was stopped by adding 1 N sulfuric acid (100 ⁇ l / well). The strength of the color reaction was measured in the ELISA reader (MWG spectral). The measurement takes place at 455 nm against the reference wavelength 620 nm.
  • HP25.2m / 2H10 proved to be a suitable detector antibody for the combination with all other antibodies tested (Tab. 5).
  • HP25.6m / 1 B5, 1G4 and 1 H4 were tested as catcher antibodies in the rapid test.
  • HP25.6m / 1 B5 turned out to be the best capture antibody.
  • the monoclonal antibodies were coupled to biotin following purification. The coupling was carried out according to known methods (Hariow & Lane, 1988). The monoclonal antibodies were conjugated at a concentration of approx. 1-2 mg / ml. Before coupling, the antibodies were buffered by dialysis in 0.1 M sodium acetate buffer, pH 8.3 or 0.1 M sodium hydrogen carbonate buffer, pH 8.3. 50 ⁇ g of N-hydroxysuccinimidobiotin (NHS-d-biotin; Sigma) in DMSO were added to each 1 mg of antibody and mixed. The mixture was incubated for 1 h at room temperature. Thereafter, the biotinylated antibodies from uncoupled NHS-d-biotin freed by extensive dialysis against 0.15 M PBS, 0.05% NaN 3 , pH 7.5.
  • NHS-d-biotin N-hydroxysuccinimidobiotin
  • Monoclonal antibodies were coupled to colloidal gold using known standard methods (Frens, 1973; Geoghegan and Ackerman, 1977; Slot et al., 1985).
  • Gold colloid with a particle size of 40 nm, OD (520 nm) 1 (British BioCell, Cambridge, England) was adjusted to pH 9 with 0.1 MK 2 CO 3 .
  • Purified mAb was dialyzed against 2 mM borate buffer, pH 9.2 and diluted to a concentration of 0.1 mg / ml. For coupling, 2 ml of the mAb solution was added dropwise to 20 ml of the gold solution with rapid stirring and incubated for 30 min at room temperature.
  • the optimal IgG concentration and the suitable pH for the coupling were determined individually for each mAb.
  • 2 ml bovine serum albumin was added in a concentration of 10% and incubated for a further 5 min.
  • Gold colloid not coupled to IgG and free IgG were then separated by centrifugation.
  • the coupling mixture was centrifuged at 15,000 RPM (Sorvall, SS-34) for 30 min and the clear supernatant was suctioned off using a vacuum.
  • the gold-IgG conjugate deposited as loose dark red sediment at the bottom of the centrifuge tube, was taken up in 2 ml 20 mM Tris, pH 8.2 with the addition of 1% bovine serum albumin and 0.05% NaN 3 .
  • An immunochromatographic test based on the sandwich principle was set up with the antibody pair HP25.2m / 2H10 and HP25.6m / 1 B5. As shown schematically in FIGS. 9 and 10, this test consists of a sample application area (1), a filter (2), a test or analysis area (3) and an absorption area (4).
  • the purified mAb HP25.2m / 2H10 was coupled to gold as a signal-forming immune reagent (British BioCell, Edinburgh, England).
  • the mAb-gold conjugate was diluted in deionized water with the addition of 5% sucrose (Sigma, Deisenhofen) to an OD (520 nm) of 3 and applied to a conjugate fleece made of glass fiber (Pall, Dreieich). The conjugate fleece was then vacuum dried.
  • test area As a test area (FIGS. 10, 3), nitrocellulose with a flow rate of 95-175 sec / 4 cm (Millipore, Bedford, MA, USA) was coated with the immunoreagents forming the test and control line. A special application device for test strips (Imagene, Hanover, NH, USA) was used for this. Purified mAb HP25.6m / 1 B5, in phosphate buffer pH 7.4 in the concentration 1-2 ⁇ g / cm, was applied as the test line (FIGS. 10, 6). A polyclonal anti-mouse antibody (Dianova, Hamburg) was applied as a control line (FIGS. 10, 7) in a concentration of 0.1-0.3 ⁇ g / cm.
  • the coated nitrocellulose and the coated conjugate fleece were then glued together with the other components of the test strip onto polyester carriers (G&L, Santa Clara, CA, USA) and cut into 5 mm wide individual strips.
  • Glass fibers (Ahlstrom, Mt. Holly Springs, PA, USA; Pall, Dreieich; Whatman, Maidstone, England) with a width of 1-2 cm were used as filters (FIGS. 10, 2).
  • Absorbent cellulose or cellulose glass fiber materials with a width of 2-3 cm were used for the absorption area (Fig. 10, 4) (Pall, Dreieich; Schleicher & Schuell, Dassel; Whatman, Maidstone, England).
  • Example 11 Rapid immunochromatographic test using streptavidin as a test line
  • the mAb HP25.6m / 1 B5 used as the test line was coupled to biotin and dried onto a second conjugate fleece in the sample application area.
  • Recombinant streptavidin (Röche, Mannheim) was coated as a test line in a concentration of 10-20 mg / ml in phosphate buffer, pH 7.4.
  • both antibody conjugates are mobile during the test and migrate over the test strip during the test.
  • the entire sandwich complex is formed during the migration, which is captured on the test line by binding biotin to streptavidin.
  • Example 12 Detection of H. pylori in human stool using an immunochromatographic rapid test
  • test result positive the stool samples were dissolved 1:15 in sample buffer and 500 ⁇ l of the sample liquid were applied to the application zone (sample application area) of the test strip. After 15 minutes, the test was evaluated visually. The test signal on the test line was classified as present (test result positive) or not present (test result negative). The reading of the test result was done independently by three people who had no qualifications as laboratory personnel. In addition, the tests were rated semi-quantitatively by the laboratory staff as 0 (negative), 1 (weakly positive) and 2 (strongly positive).
  • Table 6 shows the results obtained using the rapid stool test compared to the two reference methods when evaluating a total of 200 patient samples.
  • 100 H. py / or / -positive samples 95 were tested as true positive, with 5 samples showing a false negative result.
  • 100 H. py / or / ' -negative samples 94 samples were tested as true negative, and 6 samples showed a false positive result.
  • the sensitivity and specificity of the rapid test were 95% and 94% compared to the reference methods.
  • Table 6 Test results of the gold standard reference methods and the rapid test (semi-quantitative) when examining a total of 200 stool samples
  • Example 13 Cloning and sequence determination of the functional variable regions of immunoglobulins from hybridoma cell lines
  • the DNA regions which encode the kappa light chain and the heavy chain Fd segment (VH or CH1) of the respective antibodies were amplified by means of PCR.
  • the oligunucleotide primer set listed in Table 7 was used.
  • the cDNA isolated from the individual hybridoma cell lines served as a template.
  • the primer set used results in a 5'-Xho I and a 3'-Spe I interface in the heavy chain Fd fragments and in each case a 5'-Sac I and a 3'-Xba I interface in the kappa light chains.
  • 11 different 5'-VH primers (MVH 1-8 and MULH1-3) were combined with the 3'-VH primer MlgG2a (HP25.2m / 2H10) ) or with the 3'-VH primer MlgG1 (HP25.6m / 1 B5).
  • the isolated bands were then subjected to a restriction digest using the enzymes Xho I and Spe I (heavy chains) or Sac I and Xba I (light chains) and the fragments obtained in the plasmid vector Bluescript KS (Stratagene) cloned after it had first been cleaved with the restriction enzymes Xho I and Spe I or Sac I and Xba I.
  • Plasmid preparations of the cloned heavy and light chain fragments were then sequence analyzed. Sequences were selected which code for functional variable regions of the immunoglobulin heavy and light chain (VH or VL). In this way, exactly one functional VH and one functional VL region could be identified for this hybridoma cell line.
  • the functional VH and VL sequences are shown in Fig. 1 / Fig. 2 reproduced. The first four amino acids of the VH region were supplemented by recloning. Cloning and sequencing were carried out according to standard methods (Sambrook et al., 1989).
  • the isolated bands were then sequenced directly and a functional light chain and a functional heavy chain were identified.
  • the heavy chain Fd fragment and the light chain were then subjected to a restriction digest using the enzymes Xhol and Spei (heavy chain) or Sacl and Xbal (light chain) and the fragments obtained were converted into the plasmid vector pBSIIIHisEx (Connex) cloned after it had been cleaved with the restriction enzymes Xho I and Spe I or Sac I and Xba I, and sequenced again.
  • the functional VH and VL sequences are shown in Fig. 3 / Fig. 4 reproduced. In the VH and VL sequences, the mature N-termini are shown, as determined by sequencing using leader primer. Cloning and sequencing were carried out according to standard methods (Sambrook et al., 1989).
  • Table 7 List of the primers used for the PCR amplification of the functional variable regions of heavy and light immunoglobulin chains (orientation 5 '- 3')

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé de détection d'une infection d'un mammifère avec un micro-organisme acido-résistant, consistant à (a) mettre en oeuvre un test immuno-chromatographique et à appliquer un échantillon de selles d un mammifère comportant un antigène sur une zone d'application des échantillons de selles, à (b) incuber l'échantillon de selles avec utilisation (i) d'un récepteur sous des conditions permettant une complexation de l'antigène provenant du micro-organisme acido-résistant avec le récepteur, ou utilisation (ii) d'au moins deux premiers récepteurs différents sous des conditions permettant une complexation de l'antigène provenant du micro-organisme acido-résistant avec les deux premiers récepteurs. Le premier récepteur selon (i) ou les premiers récepteurs selon (ii) lient de manière spécifique un antigène présentant après passage dans les boyaux, pour au moins une partie des mammifères, une structure correspondant à la structure native ou à la structure contre laquelle un mammifère produit des anticorps après infection ou immunisation avec le micro-organisme acido-résistant, ou avec un extrait, un lysat, une protéine, un fragment, ou un peptide synthétique de ce micro-organisme. Ledit procédé consiste par ailleurs à (c) mettre en oeuvre un deuxième récepteur liant un complexe de récepteur d'antigène selon (b) immobilisé sur une zone d'analyse, et à (d) transporter et détecter la formation d'au moins un complexe de récepteur d'antigène selon (b) par accumulation du complexe de récepteur d'antigène sur le deuxième récepteur, dans la zone d'analyse. L'invention concerne également un test immuno-chromatographique particulièrement adapté à la mise en oeuvre du procédé selon l'invention.
EP00972748A 1999-10-12 2000-10-12 Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles Withdrawn EP1221045A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00972748A EP1221045A2 (fr) 1999-10-12 2000-10-12 Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles
DE20023799U DE20023799U1 (de) 1999-10-12 2000-10-12 Immunchromatographischer Schnelltest zum Nachweis von Säureresistenten Mikroorganismen im Stuhl

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP99120351 1999-10-12
EP99120351 1999-10-12
EP00105592 2000-03-16
EP00105592 2000-03-16
EP00107028 2000-03-31
EP00107028 2000-03-31
EP00110110 2000-05-10
EP00110110 2000-05-10
EP00972748A EP1221045A2 (fr) 1999-10-12 2000-10-12 Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles
PCT/EP2000/010057 WO2001027612A2 (fr) 1999-10-12 2000-10-12 Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles

Publications (1)

Publication Number Publication Date
EP1221045A2 true EP1221045A2 (fr) 2002-07-10

Family

ID=27513026

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00972748A Withdrawn EP1221045A2 (fr) 1999-10-12 2000-10-12 Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles

Country Status (2)

Country Link
EP (1) EP1221045A2 (fr)
DE (1) DE20023799U1 (fr)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0127612A3 *

Also Published As

Publication number Publication date
DE20023799U1 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
WO2001027612A2 (fr) Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles
EP1125130B1 (fr) Determination de la presence de micro-organismes resistant aux acides dans des selles
DE69626026T2 (de) Differentialtest für ulzerative kolitis, primäre sklerosierende cholangitis und autoimmun-hepatitis vom type 1.
EP1972938B1 (fr) Bande de test pour la détermination du risque de carie
Adams et al. Development and use of monoclonal antibody probes forimmunohistochemistry, ELISA and IFAT to detect bacterial and parasitic fish pathogens
DE69531311T2 (de) Monoklonale antikörper spezifisch für endprodukte der fortgeschrittenen glycosylation in biologischen proben
KR101994515B1 (ko) 우결핵 진단용 스트립 및 이를 이용한 우결핵 진단 방법
JPH04503754A (ja) モノクローナル抗体に基づくリステリア・モノシトゲネスの検出システムの開発
CA2132421A1 (fr) Anticorps opsoniques largement reactifs qui reagissent avec les antigenes des staphylocoques communs
US20210324055A1 (en) Methods, Devices, Kits and Compositions for Detecting Tapeworm
EP1221045A2 (fr) Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles
DE19653358A1 (de) Immunoassay zum Nachweis von MIA
DE69110067T2 (de) Monoklonale Antikörper gegen nicht-A 1C glykosyliertes Hämoglobin.
EP1913394B1 (fr) Système de test servant au dépistage de salmonelles
EP2561362B1 (fr) Procédé pour reconnaître une infection par des salmonelles
DE20023767U1 (de) Mittel zum Nachweis von Säure-resistenten Mikroorganismen im Stuhl
RU2782463C1 (ru) Способы, устройства, наборы и композиции для обнаружения ленточных червей
US20240077480A1 (en) Lateral flow assay for detecting pathogens in milk from mastitic cows
KR20230165063A (ko) 엔로플록사신에 특이적으로 결합하는 단일클론항체 및 이를 이용한 엔로플록사신 검출용 키트
JP2005220044A (ja) 抗ミティスモノクローナル抗体、それを産生する細胞株、抗ミティスモノクローナル抗体の作製方法、およびミティス検出キット

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020426

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020426;LT PAYMENT 20020426;LV PAYMENT 20020426;MK PAYMENT 20020426;RO PAYMENT 20020426;SI PAYMENT 20020426

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TRUEE, ANDREAS

Inventor name: CULLMANN, GERHARD

Inventor name: SCHWARTZ, GEORGE

Inventor name: LAKNER, MERET

Inventor name: REITER, CHRISTIAN

Inventor name: DEHNERT, SONJA

17Q First examination report despatched

Effective date: 20030808

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DAKOCYTOMATION DENMARK A/S

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DAKOCYTOMATION LTD.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OXOID (ELY) LIMITED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150602